Lowers the risk of MI, stroke, revascularization procedures, and angina. ANDA 207687, held by Accord Hlthcare. Atorvastatin Calcium.
As of Nov 16, 2026, ANDA 207687 (Atorvastatin Calcium), held by Accord Hlthcare, was first approved by FDA on Mar 30, 2018, with 6 approved supplements and 0 published complete response letters.
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 30, 2018 | Original application | Approved | None posted |
| Atorvastatin CalciumEQ 10MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 20MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 40MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 80MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Dec 5, 2024 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jun 9, 2023 | Supplement 13Labeling · Standard review | Approved | None posted |
| May 17, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 17, 2021 | Supplement 9Labeling · Standard review | Approved | None posted |
| Oct 16, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 16, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 30, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters